Caregen Co., Ltd. (KOSDAQ:214370)

Market Cap	6.69T +363.3%
Revenue (ttm)	77.86B -1.0%
Net Income	28.45B -20.5%
EPS	581.94 -20.1%
Shares Out	48.87M
PE Ratio	235.07
Forward PE	n/a
Dividend	640.00 (0.47%)
Ex-Dividend Date	n/a

Volume	122,690
Average Volume	220,488
Open	135,300
Previous Close	139,600
Day's Range	133,500 - 140,100
52-Week Range	22,750 - 153,800
Beta	0.96
RSI	63.09
Earnings Date	Feb 5, 2026

About Caregen

Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira...

• Industry: Chemicals
• Sector: Materials
• Founded: 2001
• Employees: 193
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214370

Financial Performance

In 2024, Caregen's revenue was 82.59 billion, an increase of 4.26% compared to the previous year's 79.21 billion. Earnings were 32.31 billion, a decrease of -19.07%.